Latest

3 stories

Hide weekly roundups

Wednesday, September 16

MacroGenics registers Phase 1 first-in-human trial of ADC MGC030 in solid tumors

Thursday, August 13

MacroGenics reports Q2, streamlines model, updates ADC and bispecific pipeline

MacroGenics paired second-quarter results with a completed manufacturing divestiture and fresh pipeline updates, including a Gilead option exercise and ESMO data plans.

SEC filing

Thursday, July 23

Clinical readoutMacroGenics MGC026

MacroGenics posts Phase 1 update on B7-H3 ADC MGC026 ahead of ESMO 2026

The head and neck cancer cohort cleared its Stage 1 bar and moved into Stage 2 under a Simon's two-stage design, with full data due at ESMO in October.

SEC filing